Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Milatuzumab - Immunomedics

Drug Profile

Milatuzumab - Immunomedics

Alternative Names: hCD74; hLL1; Humanised anti-CD74; IMMU-115

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Graft-versus-host disease; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma; Systemic lupus erythematosus

Most Recent Events

  • 01 Feb 2021 Immunomedics completes a phase Ib trial in Systemic Lupus Erythematosus in US (NCT01845740)
  • 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
  • 30 Sep 2020 Discontinued - Phase-I for Graft-versus-host disease (Adjunctive treatment, Combination therapy) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top